SEC Form 4 · accession 0001451612-26-000018

Kymera Therapeutics, Inc. · KYMR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Table I — non-derivative securities

Table II — derivative securities

Explanation of responses

• F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
• F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.2766 to $115.2672 inclusive.
• F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.27 to $116.2626 inclusive.
• F12The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.2731 to $117.2668 inclusive.
• F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.2728 to $118.2599 inclusive.
• F14The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.2717 to $119.035 inclusive.
• F15The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
• F16The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive.
• F17The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive.
• F18The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive.
• F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.995 to $107.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4) through (14), and (16) through (18).
• F3These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
• F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to 108.9725 inclusive.
• F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.02 to $110.0166 inclusive.
• F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.02 to $111.0075 inclusive.
• F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.1057 to $111.9188 inclusive.
• F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.1843 to $113.0139 inclusive.
• F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.2614 to $114.246 inclusive.

Remarks

Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the first of two filings.